Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | F2R | P25116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10109054 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2HSD17B10LMNATSHRGAA | |
| SCHEMBL13006890 | 0.84 | ITGB3 (0.48) | SMN1; SMN2HSD17B10ITGB3ITGA2BF2R | |
| SCHEMBL13006883 | 0.80 | KDM4E (0.51) | SMN1; SMN2HSD17B10LMNATSHRGAA | |
| SCHEMBL21004319 | 0.80 | POLB (0.50) | SMN1; SMN2HSD17B10LMNAKMT2ATSHR | |
| SCHEMBL10102870 | 0.77 | ALDH1A1 (0.41) | SMN1; SMN2LMNAKMT2APOLB | |
| SCHEMBL12139854 | 0.77 | HSD17B10 (0.49) | SMN1; SMN2HSD17B10LMNAKMT2ATSHR | |
| SCHEMBL21569625 | 0.75 | HSD17B10 (0.45) | SMN1; SMN2HSD17B10KMT2ATSHRGAA | |
| SCHEMBL19975949 | 0.75 | KMT2A (0.44) | SMN1; SMN2KMT2AHPGD | |
| SCHEMBL21569666 | 0.74 | LMNA (0.50) | SMN1; SMN2HSD17B10LMNAKMT2ATSHR | |
| SCHEMBL13006885 | 0.74 | HSD17B10 (0.42) | SMN1; SMN2HSD17B10LMNAKDM4EITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841324-B2 | Heterocyclic compounds as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2014-09-23 | — | — | US | disclosed |
| US-20120015959-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015959-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | ENPP2, HAX1, MTX1 | SMN1; SMN2 4505/4885HSD17B10 2719/4885LMNA 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.